This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutAboutExtended CoveragePK and PD ProfileGood Safety ProfileGuidelines and RecommendationsDosingRecommended DosageAdultsSpecial PopulationEfficacyIntra-abdominal InfectionRisk factorClinical efficacyUrinary Tract InfectionRisk factorClinical efficacyRespiratory Tract InfectionResistance rateImpactClinical efficacyFebrile NeutropeniaRisk factorTreatmentClinical efficacySafetyClinical & Scientific DataSupport & ResourcesSupport & ResourcesClinical UpdatesPrescribing InformationVideosWebinarsExplore Materials

Indication: Monotherapy – Sulbactam/Cefoperazone is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory tract infections, urinary tract infections (upper and lower), intra-abdominal infections, septicaemia, meningitis, skin and soft tissue infections, bone and joint infections, endometritis and other infections in the genital tract. MAGNEX® FORTE is indicated for a specific subset of patients (patients with immunocompromised febrile neutropenic cancer, patients who have undergone a bone marrow transplant).1

Clinical Efficacy

Cefoperazone/Sulbactam with 100% sensitivity is found to be the most effective drug for the therapy of UTIs: The Indian perspective

   

P. aeruginosa showed an increased resistance towards the third-generation cephalosporins and a decreased resistance towards the flouroquinolones.2

P. aeruginosa showed an increased resistance towards the third-generation cephalosporins and a decreased resistance towards the flouroquinolones.2

   

Adapted from Ahmed SM. 2012.

Imipenem, piperacillin/tazobactam and cefoperazone/sulbactam, with 100% sensitivity, and amikacin, with 87.5% sensitivity, were found to be the most effective drugs for the treatment of UTIs.2

   

Cefoperazone/Sulbactam and cefotaxime/sulbactam are equally efficacious for the treatment of CA-UTI in hospitalised patients​​​​​​

   

TitleExample Text
Rate of clinical improvement at test-of-cure visit was 87.50% and 92.00%, while microbiological cure rate was 93.75% and 84.00% with the cefoperazone/sulbactam and cefotaxime/sulbactam groups, respectively.3

   

Adapted from Makwana SP, et al. 2019.

   

Cefoperazone/Sulbactam has better efficacy compared with meropenem in gram-negative uropathogens

   

E. coli was the most common pathogen isolated, sensitive to nitrofurantoin, cefoperazone/sulbactam and aminoglycosides followed by meropenem.4

   

Adapted from Gupta P, et al. 2015

 

 

CA-UTI, catheter-associated urinary tract infection; UTI, urinary tract infection.​​​​​​​

 

References :

Magnex: Local product document. Pfizer; 2020. Version LPDMGX042020.​​​​​​​​​​​​​​Ahmed SM, Jakribettu RP, Koyakutty S, Arya B, Shakir VPA. Urinary tract infections – an overview on the prevalence and the anti-biogram of gram negative uropathogens in a tertiary care centre in North Kerala, India. J Clin Diag Res. 2012;6(7):1192-1195.​​​​​​​Makwana SP, Solanki MN, Dikshit RK. Cefoperazone + sulbactam versus cefotaxime + sulbactam combination therapy for the treatment of complicated urinary tract infections in hospitalized patients: safety and efficacy analysis. Natl J Physiol Pharm Pharmacol. 2019;9(2):187-195.​​​​​​​​​​​​​​Gupta P, Mandal J, Krishnamurthy S, Barathi D, Pandit N. Profile of urinary tract infections in paediatric patients [published correction appears in Indian J Med Res. 2015 Jun;141(6):850]. Indian J Med Res. 2015;141(4):473-477.
​​​​​​​Please click the Prescribing Information link to view the safety and adverse events information of MAGNEX®.
For the use only of registered medical practitioner, or a hospital or a laboratory.
PP-MGX-IND-0555 June 2022

Urinary Tract Infection


About

Cefoperazone/Sulbactam: ​​​​​​​Extended coverage with β-lactamase inhibition​​​​​​

Learn more


Dosing

Recommended dosage in adult ​​​​​​and special population​​​​​​​

Learn more


Safety

Explore the safety profile of cefoperazone/sulbactam​​​​​​​

Review safety profile


Clinical & Scientific Data

Cefoperazone/Sulbactam is more efficient in the treatment ​​​​​​​of infection​​​​​​​

Learn more
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-MGX-IND-0555

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023